Changes in Hong Kong stocks | Jinhai Medical Technology (02225) rose more than 6%, the minimally invasive surgical device market developed rapidly, and the company entered the gold track to replace domestic endoscopes

The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose by more than 6%. As of press release, it had risen 5.63% to HK$3.845, with a turnover of HK$10.417,700.

According to the news, according to the MordorIntelligence report, the minimally invasive surgical device market is growing rapidly as industry participants adapt to changing clinical standards and patient needs. China's minimally invasive surgical device market is one of the fastest growing surgical instrument markets in the world. The modernization of the medical system, the aging population, and the spread of advanced technologies such as robots, artificial intelligence assisted imaging, and minimally invasive surgical tools are jointly driving the growth of this market. The report also points out that the market size of China's minimally invasive surgical instrument industry is US$1.71 billion in 2025, and is expected to grow to US$2.68 billion in 2030, with a compound annual growth rate of 9.45%.

It is worth mentioning that in recent years, it has continued to cultivate in the field of endoscopy technology research and development. Jinhai Medical Technology has made many important breakthroughs, covering a series of innovative products from 4K ultra-high-definition endoscopy systems, 3D and naked eye 3D image processing systems to 4K fluorescence and future multi-spectral ultra-high definition endoscopy systems. Among them, the company's 4K3D naked eye fluorescence endoscope camera system won the 4K3D fluorescence endoscope registration certificate and became one of the leaders in the domestic high-end medical equipment field.